Vaxcyte Inc (NASDAQ:PCVX) saw an upside of 0.50% to close Friday at $52.45 after adding $0.26 on the day. The 5-day average trading volume is 680,200 shares of the company’s common stock. It has gained $52.63 in the past week and touched a new high 3 times within the past 5 days. An average of 558,725 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 507,660.
PCVX’s 1-month performance is 4.86% or $3.04 on its low of $47.60 reached on 09/07/23. The company’s shares have touched a 52-week low of $20.49 and high of $54.97, with the stock’s rally to the 52-week high happening on 06/23/23. YTD, PCVX has achieved 9.38% or $4.50 and has reached a new high 8 times. However, the current price is down -4.58% from the 52-week high price.
Insider Transactions
PCVX stock investors last saw insider trading activity on Sep 01.Wassil Jim (Chief Operating Officer) most recently sold 3,000 shares at $52.82 per share on Sep 01. This transaction cost the insider $158,447. Director, Lukatch Heath, sold 315 shares at a price of $46.12 on Jan 10. Then, on Dec 12, Director Lukatch Heath sold 335 shares at a price of $43.93 per share. This transaction amounted to $14,717.
Valuation Metrics
PCVX stock has a beta of 0.86. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 3.43.
Vaxcyte Inc’s quick ratio for the period ended June 29 was 21.76, with the current ratio over the same period at 21.76. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.01, while the total debt to equity was 0.01. The firm’s gross profit as reported stood at $2000.0 against revenue of $232.26 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 28.99% to -$68.34 million, while revenue of -$60.46 million was 11.53% off the previous quarter. Analysts expected PCVX to announce -$0.74 per share in earnings in its latest quarter, but it posted -$0.7, representing a 5.40% surprise. EBITDA for the quarter stood at more than -$96.59 million. PCVX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 69.44 million, with total debt at $15.21 million. Shareholders hold equity totaling $93.85 million.
Let’s look briefly at Vaxcyte Inc (PCVX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 61.24% to suggest the stock is trending Neutral, with historical volatility in this time period at 23.25%.
The stock’s 5-day moving average is $51.20, reflecting a +1.41% or $0.73 change from its current price. PCVX is currently trading +6.24% above its 20-day SMA, +8.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +8.28% and SMA200 by+18.32%.
Stochastic %K and %D was 63.56% and 53.31% and the average true range (ATR) pointed at 1.82. The RSI (14) points at 58.65%, while the 14-day stochastic is at 75.88% with the period’s ATR at 1.79. The stock’s 9-day MACD Oscillator is pointing at 0.23 and 0.40 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Vaxcyte Inc (NASDAQ: PCVX), TD Cowen launched coverage with an Outperform rating. Analysts offering their rating for PCVX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate PCVX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is PCVX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $58.00 and a high of $72.00, with their median price target at $68.00. Looking at these predictions, the average price target given by analysts is for Vaxcyte Inc (PCVX) stock is $66.14.
